公开(公告)号：US20150219670A1

公开(公告)日：2015-08-06

申请号：US14421382

申请日：2013-08-12

Applicant: Randox Laboratories Ltd.

Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

IPC: G01N33/68 ,  G01N33/70 ,  G01N33/573

CPC classification number: G01N33/6893 ,  C07K14/475 ,  C07K14/8139 ,  C12N9/104 ,  G01N33/573 ,  G01N33/6845 ,  G01N33/70 ,  G01N33/92 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2333/9108 ,  G01N2333/91188 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

Abstract translation: 本发明提供了将患有CKD的患者分为CKD的1-3期的方法，包括测定从患者获得的样品中生物标志物FABP1，γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平，以及 将样品中FABP1的水平与对照值和样品中的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平进行比较，对每种生物标志物的对照值范围进行比较，其中FABP1水平与对照值相比增加 并且每个生物标志物的对照值范围内的γ-GT，AST，肌酐和半胱氨酸蛋白酶抑制剂C的水平表明患者患有1期CKD或其中FABP1水平与对照值相比增加，γ-GT水平和 在每个生物标志物的对照值范围内的AST和与这些生物标志物的对照范围的上限阈值相比，肌酐和半胱氨酸蛋白酶抑制剂C的水平升高表明患者患有2期或3期CKD。

公开(公告)号：US11602757B2

公开(公告)日：2023-03-14

申请号：US16341436

申请日：2017-10-13

Applicant: Randox Laboratories Ltd.

Inventor： Stuart Jackson ,  Stephen Peter Fitzgerald ,  Ivan McConnell ,  John Lamont

IPC: B01F33/452 ,  C12N15/10 ,  B03C1/01 ,  B03C1/28 ,  B01F101/23

Abstract: There is provided a method of extracting material from a fluid method of extracting material from a fluid, the fluid being held within a fluid chamber. The method comprises drawing, with a magnetic field generating system, at least one magnetically susceptible member through the fluid around a closed path between at least three points in the chamber, said at least one member being adapted to bind to material in fluid in the chamber. The at least three points are arranged relative to each other in a shape having at least two dimensions, the magnetic field generating system being configured to move the at least on magnetically susceptible member directly between the at least three points, material in the fluid binding to the at least one magnetically susceptible member when it comes into contact with the at least one member as it moves through the fluid.

公开(公告)号：US20220349882A1

公开(公告)日：2022-11-03

申请号：US17630101

申请日：2020-07-26

Applicant: Randox Laboratories Ltd ,  Randox Teoranta

Inventor： Peter Fitzgerald ,  Ivan McConnell ,  Ciaran Richardson ,  John Lamont

IPC: G01N33/543 ,  G01N33/569

Abstract: The current invention provides a multiplex method for screening bovine samples for antibodies against several important pathogens. These pathogens include Bovine Viral Diarrhoea Virus (BVDV), Bovine Herpesvirus-1 (BoHV-1), Mycobacterium paratuberculosis (MAP), Leptospira species, Neospora caninum and Fasciola hepatica. This multiplex screening is enabled by substrates with immobilized pathogen antigens and offer multiple advantages for the routine testing of farm animals.

公开(公告)号：US20220011311A1

公开(公告)日：2022-01-13

申请号：US17294358

申请日：2019-11-15

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  John Lamont ,  Stephen Fitzgerald ,  Kathleen Williamson

IPC: G01N33/574

Abstract: The present invention provides a method for detecting the presence or risk of bladder cancer in a female patient comprising the steps of detecting the presence of a panel of biomarkers in a sample isolated from a female patient, said panel of biomarkers comprising IL-13 and IL-12p70 and one or more biomarkers selected from BTA, Midkine, PAI-1/tPA, 8OHdG, CEA, CK18, Clusterin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-Dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9NGAL, MMP9TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglycerides and/or the concentration of albumin/microalbumin/protein and creatinine expressed as an albumin:creatinine ratio in a sample isolated from a female patient; and assessing the results and comparing them to a normal control wherein an elevated presence of the biomarker compared to a normal control indicates the presence or risk of cancer in the patient from whom the sample is isolated.

公开(公告)号：US20210316312A1

公开(公告)日：2021-10-14

申请号：US17265441

申请日：2019-08-02

Applicant: RANDOX LABORATORIES LTD

Inventor： Paul Courtney ,  Martin Reid ,  Stuart Jackson ,  John Lamont ,  Ivan McConnell ,  Peter Fitzgerald

IPC: B01L9/00 ,  B01L1/00

Abstract: There is provided a pipette tip disposal assembly. The assembly comprises a receiving element adapted to support an end of at least one pipette tip, the at least one pipette tip being toppled in use from the receiving element along a first direction; and a container positioned to receive the at least one toppled pipette tip, the at least one pipette tip falling towards a base of the container on being received by the container. The base of the container has a first linear dimension aligned with the first direction corresponding to the length of a pipette tip.

公开(公告)号：US20210299655A1

公开(公告)日：2021-09-30

申请号：US17265434

申请日：2019-08-02

Applicant: RANDOX LABORATORIES LTD

Inventor： David Sloan ,  Stuart Jackson ,  John Lamont ,  Ivan McConnell ,  Peter Fitzgerald

IPC: B01L3/00

Abstract: A cartridge for polymerase chain reaction, PCR, comprises a vessel for PCR having an opening and a resealable membrane arranged, in use, to cover the opening of the vessel such that the opening of the vessel is vapour tight.

公开(公告)号：US10914745B2

公开(公告)日：2021-02-09

申请号：US15457297

申请日：2017-03-13

Applicant: Randox Laboratories Ltd.

Inventor： John Lamont ,  Ivan McConnell ,  Peter Fitzgerald

IPC: G01N33/68 ,  C12Q1/6883

Abstract: The present invention provides biomarker-based methods for diagnosing stroke in a patient suspected of having suffered a stroke, and also for discriminating between ischemic stroke and transient ischemic attack. Substrates comprising probes for specific combinations of biomarkers useful in the methods of the invention are also described.

公开(公告)号：US10753948B2

公开(公告)日：2020-08-25

申请号：US14895724

申请日：2014-06-04

Applicant: Randox Laboratories Ltd.

Inventor： Ivan McConnell ,  John Lamont ,  Peter Fitzgerald ,  Konstantinos Makris

IPC: G01N33/68

Abstract: The present invention provides a method of aiding the differential diagnosis of haemorrhagic stroke, ischemic stroke and a transient ischemic attack in a patient who has suffered or is suffering a stroke. The method comprises: (i) determining the concentration of the biomarkers VCAM-1, GFAP and CRP in an ex vivo sample obtained from the patient; and (ii) establishing the statistical significance of the concentration of the biomarkers. Optionally, the method further comprises steps of (iii) determining the concentration of the biomarkers IL-6 and sTNFR1 in an ex vivo sample obtained from the patient; (iv) determining the gender of the patient; and (v) establishing the statistical significance of the concentration of the five biomarkers, in conjunction with the patient's gender. The present invention also provides substrates comprising probes for VCAM-1, GFAP and CRP for use in a method for aiding the differential diagnosis of stroke.

公开(公告)号：US10444248B2

公开(公告)日：2019-10-15

申请号：US14421382

申请日：2013-08-12

Applicant: Randox Laboratories Ltd.

Inventor： Ivan McConnell ,  Stephen Peter Fitzgerald ,  John Lamont ,  Claran Richardson

IPC: G01N33/48 ,  G01N33/68 ,  C12N9/10 ,  G01N33/70 ,  G01N33/92 ,  C07K14/81 ,  C07K14/475 ,  G01N33/573

Abstract: The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, γ-GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of γ-GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of γ-GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of γ-GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

公开(公告)号：US20190004050A1

公开(公告)日：2019-01-03

申请号：US16065646

申请日：2016-12-23

Applicant: Randox Laboratories Ltd. ,  Randox Teoranta

Inventor： Ivan McConnell ,  Peter Fitzgerald ,  John Lamont ,  Ciaran Richardson

IPC: G01N33/574

Abstract: The present invention describes methods of determining the glycosylation signature and determining the level of a protein in a sample obtained from a patient.The present invention also describes use of a patient protein glycosylation profile to identify the presence or absence of a disease in subjects.